NICOTROL (nicotine) by Pfizer. Approved for cholinergic nicotinic agonist [epc]. First approved in 1996.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
NICOTROL is a metered nasal spray formulation of nicotine, a cholinergic nicotinic agonist approved for smoking cessation. It delivers nicotine directly through the nasal mucosa to reduce cravings and withdrawal symptoms in patients quitting tobacco. The drug acts on nicotinic acetylcholine receptors in the central nervous system to provide rapid relief during smoking cessation attempts.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), commercial teams are likely optimizing portfolio efficiency rather than driving growth.
Cholinergic Nicotinic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Nicotine Influence on the Retina Following the Use of Electronic Cigarette
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Worked on NICOTROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NICOTROL offers exposure to mature product management, competitive positioning in crowded markets, and lifecycle optimization strategies rather than launch excitement or blockbuster growth. This role suits professionals interested in defending market share, cost efficiency, and patient access in established OTC/Rx hybrid markets.